Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SeaStar and Bolt and Encourages Investors to Contact the Firm

Core Viewpoint - Class actions have been initiated on behalf of stockholders of SeaStar Medical Holding Corporation and Bolt Biotherapeutics, with deadlines for lead plaintiff petitions set for September 3, 2024 [1][9]. SeaStar Medical Holding Corporation - The class period for SeaStar is from October 31, 2022, to March 26, 2024, with a lead plaintiff deadline of September 3, 2024 [2]. - The merger between SeaStar and Legacy SeaStar was completed on October 28, 2022, resulting in Legacy SeaStar becoming a wholly owned subsidiary of SeaStar [4]. - Legacy SeaStar's Selective Cytopheretic Device (SCD) was highlighted for its potential in treating hyperinflammation and was intended for FDA approval under the Humanitarian Device Exemption for pediatric acute kidney injury [2][3]. - On May 9, 2023, SeaStar's HDE application for the SCD was rejected by the FDA, leading to a significant stock price drop of 39.69% [6]. - On March 27, 2024, SeaStar announced it would restate its financial statements for the fiscal year ended December 31, 2022, due to deficiencies in accounting treatment related to certain financial instruments [7]. Bolt Biotherapeutics - The class period for Bolt Biotherapeutics is from February 5, 2021, to May 14, 2024, with a lead plaintiff deadline of September 3, 2024 [13]. - The complaint alleges that Bolt's product BDC-1001 was less effective than represented, leading to overstated clinical and commercial prospects [9].